louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01740206: Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Attention Deficit Hyperactivity Disorder
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2012-12-04
Enrollment: 50
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients on chronic stimulant therapy for the treatment of Attention deficit hyperactivity disorder (ADHD) who are undergoing an outpatient surgical or diagnostic procedure will be randomized to one of two groups: stimulant medication administered on the day of surgery or stimulant medication withheld on the day of surgery. The choice of anesthetic pharmacology will be at the discretion of the attending anesthesiologist, but the endpoint will be a bispectral index (BIS) between 40 and 60 to ensure adequate and similar depth of anesthesia. Blood pressure, heart rate and use of vasopressors or anticholinergics will be recorded and the incidence of hypotension, bradycardia, or administration of medications will be compared between the two groups.


Eligibility criteria: Inclusion Criteria:

* Patients will be enrolled if they have been diagnosed with ADHD and have been taking amphetamines and/or methylphenidate for at least the last six months and are undergoing an outpatient surgical or diagnostic procedure.

Exclusion Criteria:

* Patients will be excluded if they are taking antidepressant medications, anxiolytic medication, analgesia medications other than acetaminophen or NSAIDs, if they have an allergy to midazolam, or a have cardiac disease.
* Procedures that entail the likelihood of blood transfusion will be excluded.

Primary outcomes:
measure: Heart Rate
timeFrame: Day 1
Secondary outcomes:
measure: Systolic Blood Pressure
timeFrame: Day 1
measure: Diastolic Blood Pressure
timeFrame: Day 1
measure: Mean Blood Pressure
timeFrame: Day 1
measure: mYPAS Measurement in Patients Receiving Midazolam
timeFrame: Day 1
measure: mYPAS Measurement in Patients Not Receiving Midazolam
timeFrame: Day 1
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
References:
Clinical trial NCT04080206: A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis
Official title: An Open Label, Comparative Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of 188-0551 Spray Versus Reference Listed Drug (RLD) Applied Every 12 Hours for 2 Weeks in Subjects With Moderate to Severe Plaque Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Plaque Psoriasis
Lead sponsor: Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2019-09-06
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is to determine and compare the adrenal suppression potential and the pharmacokinetic (PK) properties of 188-0551 Spray versus an FDA-approved drug (also known as a "Reference Listed Drug" \[RLD\]) under maximal use conditions when applied twice daily (approximately every 12 hours) in adult subjects with stable, moderate to severe, plaque psoriasis.


Eligibility criteria: Inclusion Criteria:

* Subject is a male or non-pregnant female and is at least 18 years of age at the time of informed consent.
* Subject has provided written informed consent.
* Subject has moderate or severe psoriasis involving a minimum of 20% Body Surface Area (BSA).
* Subject has an Investigator's Global Assessment (IGA) score of at least three (3 = moderate) at the Baseline Visit.

Exclusion Criteria:

* Subject is pregnant, lactating, or is planning to become pregnant during the study.
* Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.
* Subject has a physical condition which, in the investigator's opinion, might impair evaluation of plaque psoriasis, adrenal axis function or which exposes the subject to an unacceptable risk by study participation.
* Subject has had prolonged exposure to natural or artificial sources of ultraviolet radiation.
* Subject is currently enrolled in an investigational drug or device study.
* Subject has clinically significant abnormal labs at Visit 1/Screening that precludes topical steroid use, in the opinion of the investigator.

Primary outcomes:
measure: The proportion of subjects to exhibit adrenal suppression as measured by a cortrosyn stimulation test
timeFrame: Day 15
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: TI Site #13
state: Arizona
city: Thousand Oaks
country: United States
facility: TI Site #12
state: California
city: Miami
country: United States
facility: TI Site #11
state: Florida
city: Batumi
country: Georgia
facility: TI Site #31
city: Tbilisi
country: Georgia
facility: TI Site #32
city: Lviv
country: Ukraine
facility: TI Site #23
city: Rivne
country: Ukraine
facility: TI Site #22
city: Zaporizhzhya
country: Ukraine
facility: TI Site #21
Study officials:
References:
Clinical trial NCT01926106: Nasal Intermittent Positive-Pressure Ventilation for Twin Infants With Respiratory Distress Syndrome
Official title: Nasal Intermittent Positive-Pressure Ventilation vs Nasal Continuous Positive Airway Pressure for Twin Infants With Respiratory Distress Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neonatal Respiratory Distress Syndrome
Keywords: Nasal Intermittent Positive-Pressure Ventilation
Nasal Continuous Positive Airway Pressure
twin
respiratory distress syndrome
Lead sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Sponsor class: OTHER
First posted: 2013-08-20
Enrollment: 286
Sex: ALL
Minimum age (years): 30
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: In the present study, we hypothesized that primary mode nIPPV initiated shortly after birth would decrease the incidence of intubation or death in twin infants when compared to nCPAP.

Detailed description: After inclusion of eligible twins infants,one of the twins was supported by nCPAP and another nIPPV.

Eligibility criteria: Inclusion Criteria:

* Twins
* Clinical diagnosis of mild-moderate respiratory distress syndrome
* requiring a fraction of inspired oxigen (FiO2 ) \<0.40 to keep oxygen saturation of 90%-95%
* a chest X-ray suggestive of early stage hyaline membrane disease, (i.e. mild microgranulia and air bronchogram)

Exclusion Criteria:

* pneumothorax
* pneumomediastinum
* surgical diseases
* cardiac diseases
* intraventricular hemorrage
* major congenital defects

Primary outcomes:
measure: incidence of intubation
timeFrame: 48h
Secondary outcomes:
measure: incidence of BPD
timeFrame: 1 month
Other outcomes:
measure: death
timeFrame: 3 months
Locations:
city: Chongqing
country: China
facility: Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University
state: Chongqing
Study officials:
affiliation: Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University,
name: Long Chen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00444106: Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function
Official title: An Open-label, Randomized, Single-center, Parallel Group Study of the Effects of Artemether-lumefantrine (Coartem®) Atovaquone-proguanil (Malarone®) and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Malaria
Falciparum
Keywords: Malaria
hearing
co-artemether
auditory
Plasmodium falciparum
marsh fever
Plasmodium infections
remittent fever
paludism
artemether
artemisinins
benflumetol
lumefantrine
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2007-03-07
Enrollment: 265
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the potential effects of artemether- lumefantrine on the auditory function


Eligibility criteria: Inclusion Criteria

* 12 years of age or older
* Accepts Healthy Volunteers
* P. falciparum parasitemia between 1,000 and 100,000 parasites/μl
* History of fever or presence of fever (temperature ≥ 37.5°C)

Exclusion Criteria

* Signs/symptoms of severe/complicated malaria
* Ingestion of various antimalarial drugs, or antibiotics in the previous 2 weeks to 2 months
* History of any drug-related hearing impairment
* Abnormal hearing function at study entry
* Exposure to sustained loud noises, by self-report, within the past 24 hours
* Present ear problems
* Pregnant or lactating (urine test for β-HCG) to be performed on any woman of child bearing age)

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes on Day 7(a Type of Hearing Test)
timeFrame: 7 days
Secondary outcomes:
measure: Auditory Changes Following 3 Days of Treatment at Days 3, 7, 28, and 42 Days as Assessed by Pure Tone Thresholds Assessments (a Type of Hearing Test)
timeFrame: Baseline (Day 1), 3, 7, 28 and Day 42
measure: Relationship Between Changes in Auditory Function and Treatment Groups
timeFrame: From Baseline to Day 7
measure: Efficacy of Polymerase Chain Reaction (PCR) Adjusted Malaria Cure Rates of the Three Treatment Regimens at Days 14, 28 and 42
timeFrame: Days 14, 28 and 42
Other outcomes:
Locations:
city: Tumaco
country: Colombia
facility: Novartis Investigational Site
Study officials:
affiliation: Novartis
name: Novartis
role: STUDY_DIRECTOR
References:
Clinical trial NCT06578806: Tooth Loss Rate and Its Associated Factors: a Retrospective Cross-sectional Study With up to 50 Years of Follow-up.
Official title: Tooth Loss Rate and Its Associated Factors in Adult Population: a Retrospective Cross-sectional Study With up to 50 Years of Follow-up.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tooth Loss
Keywords: active therapy
bruxism
cardiovascular disease
diabetes
periodontitis
smoking
supportive periodontal therapy
tooth loss
tooth loss rate
Lead sponsor: Saint-Joseph University
Sponsor class: OTHER
First posted: 2024-08-29
Enrollment: 448
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with generalized chronic periodontitis or gingivitis.

Brief summary: This study will evaluate, in an adult population (n=448) previously diagnosed with gingivitis and/ or periodontitis, the tooth loss rate and its potential associated factors such as diabetes, smoking, bruxism, cardiovascular diseases, and also the effect of supportive periodontal therapy on these factors, with an up to 50 years of follow-up period.

Significant results of the present study will help in the future reduction of tooth loss among periodontally involved patients.


Eligibility criteria: Inclusion Criteria:

* Age \> 20 years.
* Patients diagnosed with generalized chronic periodontitis or gingivitis.
* At least 10 years of follow-up after 1st visit.
* All treatments and recall sessions were done by the same operator at the same specialized dental clinic.

Exclusion Criteria:

* Patients with healthy periodontal status.
* Patients with orofacial anomalies and syndromes.
* Patients receiving periodontal treatments by different operators.
* Patients receiving periodontal treatments at different clinics.
* Patients receiving bisphosphonate therapy.
* Patients receiving chemotherapy or radiotherapy.
* Patients receiving a hormonal therapy.
* Patients with a history of refractory periodontitis or repeated abscess formation.
* Patients with debilitating diseases that could impair the immune system (HIV/AIDS, cancer, or autoimmune diseases).

Primary outcomes:
measure: Tooth loss rate
timeFrame: From 10 up to 50 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Saint Joseph University of Beirut, Faculty of dental Medicine, Periodontolgy department
name: Carole CHAKAR, PHD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03120806: Interrupted Versus Continuous Subcuticular Skin Suturing in Elective Cesarean Section.
Official title: Comparative Study Between Interrupted and Continuous Subcuticular Skin Suturing in Women Undergoing Elective Cesarean Section. A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cesarean Section Wound
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-04-19
Enrollment: 169
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Non-diabetic pregnant women who undergo elective CS will be randomized into two groups: group I included women who has their skin closed with subcuticular interrupted mattress suture using non-absorbable polypropylene, and group II included women who has their skin closed with subcuticular continous suture using the same suture material

Detailed description: Non-diabetic pregnant women who undergo elective CS will be randomized into two groups: group I included women who had their skin closed with subcuticular interrupted mattress suture using non-absorbable polypropylene, and group II included women who had their skin closed with subcuticular continous suture using the same suture material.

Eligibility criteria: Inclusion Criteria:

* 18 years or older
* Overall good health
* Elective Cesarean section ASA class 1 or 2

Exclusion Criteria:

* Allergy to synthetic suture materials
* Diabetes whether gestational or pregestational
* use of steroid or immunosuppresive medication within last 6 month of procedure
* Skin sepsis or systemic fever
* BMI \> 35
* History of keloid or hypertrophic scar formation or dermatologic conditions known to impair wound healing ASA class 3 or 4

Primary outcomes:
measure: wound infection
timeFrame: 10 days after surgery
Secondary outcomes:
measure: scar dehiscence
timeFrame: 10 days after surgery
measure: wound seroma
timeFrame: 10 days after surgery
measure: the need for reclosure
timeFrame: 10 days after surgery
measure: postoperative pain
timeFrame: 12 hours after surgery
measure: wound hematoma
timeFrame: 10 days after surgery
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr Alainy medical school
Study officials:
affiliation: Kasr Alainy medical school
name: Ahmed Maged, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01863706: Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage
Official title: Safety and Efficacy of Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Post Partum Hemorrhage
Keywords: Misoprostol
Oxytocin
Post Partum Hemorrhage (PPH)
Third stage of labour
Lead sponsor: Hormozgan University of Medical Sciences
Sponsor class: OTHER
First posted: 2013-05-29
Enrollment: 400
Sex: FEMALE
Minimum age (years): 10
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Post partum Hemorrhage (PPH) is one of three main causes of death in pregnant women. Oxytocin is widely used for prevention of PPH. Some studies suggested misoprostol as an alternative treatment when Oxytocin isn't available. The aim of this study is to compare the safety and efficacy of Oxytocin and misoprostol for prevention of PPH.

Detailed description: In a double blind randomized controlled trial 400 pregnant women who has vaginal delivery at Shariati hospital are assigned into two groups either to receive 20 unite oxytocin in 1000cc ringer and 2 placebo tablet or 400mcg oral misoprostol and 2cc normal saline in 1000cc ringer.

Eligibility criteria: Inclusion Criteria:

* were women with singleton pregnancy
* with cephalic presentation
* who had NVD spontaneously or by induction

Exclusion Criteria:

* placenta previa
* placental detachment
* coagulation problems
* previous CS
* macrosomia
* Polyhydramnios
* and uncontrolled asthma

Primary outcomes:
measure: Amount of bleeding
timeFrame: 1 hour
Secondary outcomes:
measure: Hemoglobin decrease
timeFrame: 24 hours
measure: Hematocrite decrease
timeFrame: 24 hours
Other outcomes:
measure: Side effects
timeFrame: 24 hours
Locations:
city: Bandar Abbas
country: Iran, Islamic Republic of
facility: Hormozgan University of Medical Sciences
state: Hormozgan
Study officials:
affiliation: Hormozgan University of Medical Sciences
name: Minoo Rajaei, Dr
role: STUDY_CHAIR
affiliation: Hormozgan University of Medical Sciences
name: Zohreh Shahboodaghi, Dr
role: STUDY_DIRECTOR
References:
citation: Rajaei M, Karimi S, Shahboodaghi Z, Mahboobi H, Khorgoei T, Rajaei F. Safety and efficacy of misoprostol versus oxytocin for the prevention of postpartum hemorrhage. J Pregnancy. 2014;2014:713879. doi: 10.1155/2014/713879. Epub 2014 Mar 5.
Clinical trial NCT04693806: The Effect of Embryo Culture Under a Continuous CO2 Setting Versus a Sequential CO2 Setting
Official title: The Effect of Embryo Culture Under a Continuous CO2 Setting Versus a Sequential CO2 Setting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Lead sponsor: Reproductive Medicine Associates of New Jersey
Sponsor class: OTHER
First posted: 2021-01-05
Enrollment: 102
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to determine if embryo culture under a single CO2 setting improves blastocyst formation rate.

Detailed description: Following enrollment, patients will undergo ovarian stimulation and oocyte retrieval per routine as previously consented to at the clinic. IVF stimulation protocol will be at the discretion of the patient's individual provider, per routine. Intracytoplasmic Sperm Injection (ICSI) will be performed and embryos will be cultured to the blastocyst stage per routine. There are no changes to the embryology care itself, the only difference within the study is the CO2 level within the incubator pending the patient's randomization.

Eligibility criteria: Major Inclusion Criteria for participants:

1. Patients undergoing IVF stimulation cycle with plan for subsequent FET

Major Exclusion Criteria for participants:

1. All patients who do not voluntarily give their written consent for participation
2. Male partner with \<100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable)
3. Use of surgical procedures to obtain sperm

Primary outcomes:
measure: blastulation rate
timeFrame: approximately one week
Secondary outcomes:
Other outcomes:
Locations:
city: Basking Ridge
country: United States
facility: Reproductive Medicine Associates of New Jersey
state: New Jersey
Study officials:
References:
Clinical trial NCT04210206: Short-term Effects of Good Metabolic Control on Cognitive Function, Wellbeing, and Metabolic Parameters in Adult Patients With Phenylketonuria
Official title: Kurzfristiger Einfluss Einer Guten Stoffwechseleinstellung Auf Kognitive Funktion, Wohlbefinden Und Stoffwechselparameter Bei Erwachsenen Patienten Mit Phenylketonurie (Short-term Effects of Good Metabolic Control on Cognitive Function, Wellbeing, and Metabolic Parameters in Adult Patients With Phenylketonuria)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Phenylketonurias
Keywords: cognitive function adults
Lead sponsor: Ludwig-Maximilians - University of Munich
Sponsor class: OTHER
First posted: 2019-12-24
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to evaluate if in adult patients with phenylketonuria (PKU) without strict metabolic control during the last 12 months, strict metabolic control for 8 weeks results in an improvement of cognitive function.


Eligibility criteria: Inclusion Criteria:

* Men and women with classical PKU
* Age ≥ 18 years
* Good metabolic control during childhood (at least until 12 years of age)
* Plasma Phe levels ≥ 15 mg/dl for ≥ 1 year
* Written informed consent prior to study participation

Exclusion Criteria:

* Reduced cognitive function (unability to perform test battery)
* Drug and or alcohol abuse
* Treatment with BH4
* Treatment with drugs known to affect cognitive function

Primary outcomes:
measure: Spatial working memory strategy index
timeFrame: 8 weeks
Secondary outcomes:
measure: Reaction time
timeFrame: 8 weeks
measure: Paired Associates Learning
timeFrame: 8 weeks
measure: Multitasking Test
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Munich
country: Germany
facility: University Munich
Study officials:
References:
Clinical trial NCT05748106: Comparison of a Novel Ultrasound System Versus Standard Imaging Modalities
Official title: Comparison of a Novel Ultrasound System Versus Standard Imaging Modalities in the Context of Interventional Radiologic Procedures
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Image-Guided Biopsies and/or Ablations
Keywords: Ultrasound Imaging
Interventional Radiology
Image-guided biopsy
Image-guided tumor ablation
Image-guided procedures
Lead sponsor: MAUI Imaging, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Texas Health Resources
First posted: 2023-02-28
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patient undergoing a standard / routine interventional radiologic procedure

Brief summary: This is an observational study comparing a novel ultrasound-based imaging system (MAUI K3900) to standard-of-care (SoC) imaging systems used to guide and/or manage interventional radiologic procedures such as solid organ biopsies or lesion ablations.

Detailed description: The purpose of this study is to obtain images using the MAUI Imaging Inc.'s K3900 Ultrasound System and compare them to images captured with FDA cleared imaging devices including traditional ultrasound, CT, MRI and Xray, and to study device safety. The information obtained in this study will inform MAUI Imaging as to what specific follow-on studies will be done in support of appropriate FDA clearances and/or claims. No diagnostic or patient management decisions will be made using the MAUI K3900 Ultrasound System in this study.

Eligibility criteria: Inclusion Criteria:

* Undergoing standard / routine interventional radiologic procedure

Exclusion Criteria:

* Unwilling or unable to provide informed consent

Primary outcomes:
measure: Usefulness relative to standard imaging for image-guided solid organ biopsies and/or ablations
timeFrame: Up to 26 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Texas Health Presbyterian Hospital
state: Texas
Study officials:
affiliation: MAUI Imaging, Inc.
name: John C Cheronis, MD/PhD
role: STUDY_DIRECTOR
References: